Drugs / CovenD24
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04902183 | Jun → Sep 2021 | COVID-19 | Athens Medical Society | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CovenD24 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04902183 ↗ |
| Modality | Other / unclassified | “exosomes overexpressing CD24” NCT04902183 ↗ |
| Route | Inhaled | “The exosomes will be diluted in normal saline for inhalation via mouthpiece nebulization” NCT04902183 ↗ |